Josh Nathan-Kazis

Third-quarter adjusted earnings per share was $1.09, confirming preliminary numbers from October. A Trump victory is also seen as beneficial as it's likely to benefit Medicare Advantage players.

Novo said Wegovy had 215,000 prescriptions per week in the U.S., up from roughly 100,000 in January.

Third-quarter adjusted earnings per share are $1.09, confirming preliminary numbers from October. A Trump victory is also seen as beneficial for Medicare Advantage players.

Moderna third-quarter financial results look far better than analysts anticipated, but the beat seems largely to reflect Americans getting their Covid-19 shots earlier this year than they did last year. An earnings beat based on cost cuts and an early launch of this year’s Covid vaccine, however, seems unlikely to change the narrative on the stock, which is down nearly 50% this year coming into Thursday’s session. Net income was $13 million for the quarter, substantially better than the loss of $769 million analysts had anticipated, according to FactSet.

A new Department of Justice lawsuit has put at risk UnitedHealth Group effort to buy Amedisys one of the country’s largest providers of home health and hospice care for older people. UnitedHealth itself is already one of the largest providers of home health and hospice care in the U.S. In a suit seeking to block the deal, filed Tuesday in a federal district court in Maryland, the DOJ’s antitrust division argued that the combination would hurt consumers and the nurses who work for the companies. In addition to the DOJ’s antitrust division, the suit was also brought by state attorneys general from Maryland, Illinois, New Jersey, and New York.

The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive marketing campaigns to sell low-cost generics online.

The prospect of Kennedy leading HHS or a similar agency has cast major uncertainties over the health system.

The decision makes it impossible to guess what might come next for the healthcare industry. Robert F. Kennedy Jr. is unlike anyone else to ever hold the position.

Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health and Human Services.

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine sold by Novo Nordisk —jumped as soon as the filing appeared on the court website, and ended the day up 11%. The continued delay from the FDA creates even more uncertainty in the market for GLP-1 obesity drugs, which has been flooded with legal, low-price knockoffs of Lilly’s Zepbound and Novo’s Wegovy.